Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a

Protocol: L044L
______________________________________________________________________________

| 596 |L04AA11| ETANERCEPTUM**** | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L04AA11 ETANERCEPTUM PULB. + SOLV. PT.

SOL. INJ. 25 mg

ENBREL 25 mg 25 mg WYETH EUROPA LIMITED

L04AA11 ETANERCEPTUM PULB + SOLV. PT.

SOL. INJ. 50 mg

ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB. + SOLV. PT.

SOL. INJ. 25 mg

ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB + SOLV. PT.

SOL. INJ. 50 mg

ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM SOL. INJ. ÎN SERINGĂ

PREUMPLUTĂ 25 mg

ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM SOL. INJ. ÎN SERINGĂ 50 mg

PREUMPLUTĂ

ENBREL 50 mg 50 mg WYETH EUROPA LIMITED

________________________________________________________________________________

______________________________________________________________________________

| 597 |L04AA12| INFLIXIMABUM**** | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L04AA12 INFLIXIMABUM PULB. PT. CONC. PT. 100 mg

SOL. PERF.

REMICADE 100 mg 100 mg CENTOCOR B.V.

________________________________________________________________________________
______________________________________________________________________________

| 598 |L04AA21| EFALIZUMABUM**** | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L04AA21 EFALIZUMABUM PULB + SOLV. PT.

SOL. INJ. 100 mg/ml

RAPTIVA 100 mg/ml 100 mg/ml SERONO EUROPE LTD.

________________________________________________________________________________
______________________________________________________________________________

| 599 |L04AA17| ADALIMUMABUM**** | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L04AA17 ADALIMUMABUM SOL. INJ. ÎN SERINGĂ 40 mg

PREUMPLUTĂ

HUMIRA 40 mg 40 mg ABBOTT LABORATORIES LTD.

________________________________________________________________________________
SUBLISTA C2 - P1: PROGRAMUL NAŢIONAL DE BOLI TRANSMISIBILE. A) SUBPROGRAMUL DE TRATAMENT ŞI MONITORIZARE A PERSOANELOR CU INFECŢIE HIV/SIDA ŞI TRATAMENTUL POSTEXPUNERE
______________________________________________________________________________

| 600 |J05AE01| SAQUINAVIRUM | |

|_______|_______|____________________________________________|_________________|
Prescriere limitată: Tratamentul infecţiei HIV la pacienţii cu: celule CD4 < 500 pe mm cub sau încărcare virală > 10.000 copii per ml.